Skip to content

All recalls FDA

FDADrugsRecalled Status: Ongoing

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules

Class IIofficial

FDA Class II

FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.

Hazard
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Products
  • Duloxetine Delayed-Release Capsules
Where it was sold

U.S. Nationwide

Nationwide

Units affected
172,263 bottles
About this recall
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922.